The FDA says Summit and Akeso’s lung-cancer application did not establish a statistically significant overall-survival benefit, delaying a potential first U.S. approval for a new class of cancer drug.
The U.S. Food and Drug Administration has declined to approve Summit Therapeutics and Akeso’s ivonescimab with platinum chemotherapy for certain patients with previously treated, EGFR-mutated advanced lung cancer, saying the application does not establish a clear enough survival benefit.
In a Complete Response Letter issued Nov. 15, the agency said the Phase 3 HARMONi trial failed to demonstrate a statistically significant improvement in overall survival. The trial showed a progression-free-survival benefit, but the FDA said that result alone did not support a favorable benefit-risk profile, according to pharmaphorum’s report and trial details reported by the companies.
The decision delays the first U.S. approval of a PD-1×VEGF bispecific antibody, a drug designed to target two biological pathways. The application covered patients with locally advanced or metastatic non-small-cell lung cancer, an EGFR mutation and prior treatment. Akeso, based in China, developed ivonescimab and markets it there; Summit holds rights outside China. The application had also become a test of whether a cancer medicine developed in China could pass U.S. regulatory review, the Financial Times reported.
For patients whose cancer has progressed after treatment, the distinction between delaying disease progression and extending life matters. Progression-free survival measures how long patients live without their disease worsening; overall survival measures how long they live. The FDA’s decision makes clear that, in this application, the progression-free-survival result did not substitute for evidence of a statistically significant survival improvement.
Summit said HARMONi showed a positive overall-survival trend. It also cited a post-hoc longer-follow-up analysis reporting a hazard ratio of 0.76 in the full population and among Asian and Western patients. A hazard ratio compares the rate of an event between study groups over time; a figure below one can favor treatment, but does not by itself establish statistical significance. Because the analysis was post hoc, it is distinct from meeting the trial’s prespecified statistical standard. The company’s findings therefore do not negate the FDA’s stated conclusion about the pivotal trial.
Treatment-related adverse events led to discontinuation for 16 patients, or 7.3%, receiving ivonescimab plus chemotherapy, compared with 11 patients, or 5.0%, receiving placebo plus chemotherapy. Treatment-related deaths were reported in four patients, or 1.8%, in the ivonescimab group and five, or 2.3%, in the placebo group. These figures do not show more treatment-related deaths in the drug group, but they do not answer the FDA’s central concern about efficacy or establish that the treatment is safer overall.
The available reports do not give a potential U.S. price for ivonescimab, so its effect on patient bills or insurer spending cannot be assessed. The FDA decision does not set a price or determine future coverage. The immediate question is whether the evidence is strong enough to justify approval of an additional treatment for patients and payment for it by insurers.
The letter is not a finding that ivonescimab has no effect, or that it could never be approved. It means the FDA will not approve the application in its current form based on the evidence submitted. Summit’s reported survival trend and follow-up analysis now sit alongside the agency’s conclusion that HARMONi did not demonstrate the statistically significant survival gain needed to support approval.

